Bristol-Myers Squibb gets rated a hold ... so I will wait on the next significant dip and a cooling of the valuation before considering a buy, in addition to a better debt-to-equity picture.

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

Financial discipline remained a priority, with approximately $1.1 billion of the targeted $1.5 billion in savings already realized. The company has identified an additional $2 billion in savings, with ...

Looking at Bristol-Myers Squibb Company's (NYSE:BMY ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s blockbuster Dupixent. Last year, BMS reported a phase 3 trial in eosinophilic ...

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 150 points on Thursday. The Dow ...

Bristol Myers Squibb (BMY) ended the recent trading session at $56.81, demonstrating a -0.58% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.16%.

Ratings for Bristol-Myers Squibb BMY were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ...

As the major cost-cutting initiative at Bristol Myers Squibb rolls on, the company has launched another round of layoffs in ...

Bristol Myers Squibb believes Alzheimer's treatment is the largest potential market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars ...

David Risinger’s rating is based on the impressive launch performance of Bristol-Myers Squibb’s Cobenfy, which is showing strong sales momentum since its introduction for schizophrenia treatment.

Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical company with a market capitalization of nearly $120 billion, finds itself at a critical juncture as it navigates a complex landscape of ...